The myth
A government database entry proves the product was reviewed.
The fact
In the September 2026 record, FDA says a National Drug Code listing does not establish product approval or verification of the listed information.
Basis: Read the source record
Legal and cost information is dated September 26, 2026.
FDA refers to the federal drug agency—the Food and Drug Administration.
Sources for this section
Name the product, not just the ingredient
Proteins are built from amino acids; a short chain of those parts is called a peptide. That description does not tell the reader whether a proposed product is an approved medicine. Keep the ingredient name, product name, and product form together when asking about it.
The September 2026 United States record includes approved semaglutide products (Ozempic, Wegovy), as well as approved tirzepatide products (Mounjaro, Zepbound). Those names are examples of specific reviewed medicines, rather than approval of everything described as peptide care.
The form matters too. By September 2026, the names Ozempic and Wegovy each covered tablets as well as injections. A broad statement about a brand can miss which form and label a page is discussing.
Sources for this section
Know what the listing does not establish
The government directory identifies drug products by National Drug Code, or NDC, numbers. FDA states that receiving a code does not mean the product is approved, and a listing does not mean FDA has verified the submitted information. That distinction remained explicit in the September 2026 record.
A link can be real while the conclusion drawn from it is wrong. Ask the person making the claim to identify the approval record for the exact product and the label that applies to the proposed use. Do not substitute a screenshot of a code for those answers.
The same care applies to the words “registered facility.” Under the federal rules recorded in September 2026, a drug maker does not gain FDA approval by registering its facility or listing its medicines. Registration records the place; it is not approval of what it makes. Health care providers themselves do not receive FDA approval either, the agency says.
Sources for this section
Separate review from suitability
Even a clear product identity leaves another question: why is it being discussed for this person’s concern? Ask what health problem FDA approved this exact medicine to treat, what evidence supports the use being proposed for you, and what remains uncertain. Here, the label means the medicine’s official prescribing information, not insurance coverage. A record about the product does not describe the whole person sitting in the visit.
Compounded medicines are made by a pharmacy, doctor, or registered facility instead of supplied as a finished manufactured drug. The September 2026 record says they do not carry FDA approval, and FDA does not verify their safety, effectiveness, or quality before marketing. The fact that an ingredient also appears in an approved product does not transfer that product’s review to a compounded medicine.
For a new claim, write down exactly what is being claimed before opening the source. Is it about the product’s status, an ingredient, a study result, or a person’s care? Then look for a record that addresses that same question. This simple step helps avoid asking a source to prove something it never studied.
If the answer remains unclear, keep it as an open question for the prescriber. A clear explanation can name both what the record supports and what it leaves unresolved. An incomplete link can remain an open question.
- Which exact product and form does the claim concern?
- Where is the approval record?
- What does that record leave unanswered for this visit?